Three deaths possibly linked to coronavirus vaccines have been reported in Belgium since the start of the vaccination campaign, according to data from the country’s Federal Drug Administration published by the French-language newspaper Le Soir.
More than 4.3 million people in Belgium have already received at least one dose vaccine against Covid-19. According to AFMPS data released on Thursday (27/05), 15,852 post-vaccine adverse reactions have been reported, of which 64% are ‘non-serious’.
In most cases, it is fever, muscle pain, fatigue and injection site reactions. These discomforts usually disappear after a few days and appear to occur more often after the second dose with Pfizer and Moderna and after the first dose with AstraZeneca.
However, as relayed by the Athenian-Macedonian News Agency, “3,266 reports of side effects are considered serious, the vast majority of which lead to temporary inability to work or leave home.”
130 deaths have also been reported, but only three are considered “possibly related” to the vaccine. The two deaths are probably related to the Vaxzevria drug developed by AstraZeneca and the third occurred after the Johnson & Johnson vaccine was given, after thrombosis and thrombocytopenia and “possibly related to the vaccine”.
The Belgian Federal Medicines Agency warns health professionals to be careful about the onset of this rare syndrome, which can occur within three weeks of vaccination. Shortness of breath, chest pain, swelling or pain in one leg, persistent abdominal pain, neurological symptoms or even small pieces of blood under the skin outside the injection site should ring the alarm bell. As a result of this death, it was decided not to give the J&J vaccine to people under the age of 41.
“Experience based on 209 million doses in Europe, 60 million in the United Kingdom and 286 million in the United States confirms that ‘the benefit-risk ratio of Covid-19 vaccines remains positive,'” AFMPS reassures.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
